Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Capital Expenditures for 16 consecutive years, with -$1.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 100.04% to -$1.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97903.0 through Dec 2025, up 47.31% year-over-year, with the annual reading at $97903.0 for FY2025, 47.31% up from the prior year.
  • Capital Expenditures hit -$1.0 in Q4 2025 for Cumberland Pharmaceuticals, down from $23788.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $137255.0 in Q2 2022 to a low of -$153528.0 in Q4 2022.
  • Historically, Capital Expenditures has averaged $32565.6 across 5 years, with a median of $26736.0 in 2022.
  • Biggest YoY gain for Capital Expenditures was 810.6% in 2022; the steepest drop was 1797.0% in 2022.
  • Year by year, Capital Expenditures stood at $9047.0 in 2021, then crashed by 1797.0% to -$153528.0 in 2022, then surged by 131.7% to $48673.0 in 2023, then tumbled by 95.31% to $2283.0 in 2024, then crashed by 100.04% to -$1.0 in 2025.
  • Business Quant data shows Capital Expenditures for CPIX at -$1.0 in Q4 2025, $23788.0 in Q3 2025, and $26486.0 in Q2 2025.